Abb Vie Inc. ABBV
We take great care to ensure that the data presented and summarized in this overview for AbbVie Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ABBV
View all-
Vanguard Group Inc Valley Forge, PA170MShares$28.4 Billion0.62% of portfolio
-
Black Rock Inc. New York, NY143MShares$23.8 Billion0.61% of portfolio
-
State Street Corp Boston, MA78MShares$13 Billion0.64% of portfolio
-
Jpmorgan Chase & CO New York, NY51.3MShares$8.53 Billion0.85% of portfolio
-
Capital International Investors Los Angeles, CA48.1MShares$8 Billion1.81% of portfolio
-
Geode Capital Management, LLC Boston, MA37.5MShares$6.24 Billion0.64% of portfolio
-
Morgan Stanley New York, NY35.2MShares$5.85 Billion0.52% of portfolio
-
Capital Research Global Investors Los Angeles, CA31.3MShares$5.21 Billion1.33% of portfolio
-
Charles Schwab Investment Management Inc San Francisco, CA22.7MShares$3.78 Billion0.96% of portfolio
-
Northern Trust Corp Chicago, IL20.3MShares$3.37 Billion0.65% of portfolio
Latest Institutional Activity in ABBV
Top Purchases
Top Sells
About ABBV
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Insider Transactions at ABBV
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
May 03
2024
|
Jennifer L. Davis |
BUY
Grant, award, or other acquisition
|
Direct |
1,322
+50.0%
|
-
|
May 03
2024
|
Frederick H Waddell |
BUY
Grant, award, or other acquisition
|
Direct |
1,322
+4.55%
|
-
|
May 03
2024
|
Glenn F Tilton |
BUY
Grant, award, or other acquisition
|
Direct |
1,322
+2.56%
|
-
|
May 03
2024
|
William H.L. Burnside |
BUY
Grant, award, or other acquisition
|
Direct |
1,322
+4.88%
|
-
|
May 03
2024
|
Rebecca B Roberts |
BUY
Grant, award, or other acquisition
|
Direct |
1,322
+9.55%
|
-
|
May 03
2024
|
Melody B Meyer |
BUY
Grant, award, or other acquisition
|
Direct |
1,322
+7.96%
|
-
|
May 03
2024
|
Brett J Hart |
BUY
Grant, award, or other acquisition
|
Direct |
1,322
+6.75%
|
-
|
May 03
2024
|
Roxanne S Austin |
BUY
Grant, award, or other acquisition
|
Direct |
1,322
+3.43%
|
-
|
May 03
2024
|
Thomas C Freyman |
BUY
Grant, award, or other acquisition
|
Direct |
1,322
+1.04%
|
-
|
May 03
2024
|
Robert J Alpern |
BUY
Grant, award, or other acquisition
|
Direct |
1,322
+3.7%
|
-
|
May 03
2024
|
Edward J Rapp |
BUY
Grant, award, or other acquisition
|
Direct |
1,322
+4.05%
|
-
|
May 03
2024
|
Susan E Quaggin |
BUY
Grant, award, or other acquisition
|
Direct |
1,322
+50.0%
|
-
|
Mar 20
2024
|
Nicholas Donoghoe EVP, CHIEF BUS/STRAT OFFICER |
SELL
Open market or private sale
|
Direct |
21,082
-27.38%
|
$3,710,432
$176.3 P/Share
|
Mar 18
2024
|
Jeffrey Ryan Stewart EVP, CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
58,949
-19.5%
|
$10,492,922
$178.86 P/Share
|
Mar 18
2024
|
Jeffrey Ryan Stewart EVP, CHIEF COMMERCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
26,110
+17.88%
|
$1,592,710
$61.36 P/Share
|
Mar 01
2024
|
Timothy J. Richmond EVP, CHIEF HR OFFICER |
SELL
Open market or private sale
|
Direct |
75,680
-34.96%
|
$13,395,360
$177.04 P/Share
|
Mar 01
2024
|
Timothy J. Richmond EVP, CHIEF HR OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
45,700
+33.8%
|
$2,787,700
$61.36 P/Share
|
Feb 29
2024
|
Perry C Siatis EVP, GC AND SECRETARY |
SELL
Open market or private sale
|
Direct |
9,891
-28.32%
|
$1,750,707
$177.54 P/Share
|
Feb 29
2024
|
Robert A. Michael PRES & CHIEF OPERATING OFFICER |
SELL
Open market or private sale
|
Direct |
68,879
-22.64%
|
$12,122,704
$176.45 P/Share
|
Feb 29
2024
|
Robert A. Michael PRES & CHIEF OPERATING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
21,560
+6.24%
|
$1,250,480
$58.11 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 678K shares |
---|---|
Acquisition or disposition by will or laws | 129 shares |
Exercise of conversion of derivative security | 174K shares |
Payment of exercise price or tax liability | 292K shares |
---|---|
Open market or private sale | 540K shares |
Bona fide gift | 46.2K shares |
Sale (or disposition) back to the issuer | 2.92K shares |